BNF December 2022 Update

This update contains 1 significant change, 4 dose changes, 4 new monographs and 2 new preparations.

Significant Changes:

• Herpesvirus infections: updated guidance for post-exposure prophylaxis

Dose Changes:

• Budesonide [update to dosing for intranasal administration for rhinitis and nasal polyps]
• Jorveza® (budesonide) [update to dosing for eosinophilic oesophagitis]
• Lacosamide [update to age range for monotherapy and adjunctive treatment of focal seizures with or without secondary generalisation]
• Melatonin [update to dosing for jet lag]

New Monographs:

• Imcivree® [setmelanotide]
• Kapruvia® [difelikefalin]
• Oxbryta® [voxelotor]
• Qinlock® [ripretinib]

New Preparations:

• Actimorph® [morphine]
• Dificlir® [fidaxomicin]

For further details on changes in the BNF click on: https://www.medicinescomplete.com/#/content/bnf/PHP107699